Volition Automates Vet Cancer Test with Fujifilm in Japan
Event summary
- Volition completed validation of its automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems in Japan, replacing manual plates with full automation.
- The test is now available on Fujifilm's central reference laboratories, serving over 1,700 registered veterinary hospitals in Japan.
- The automated test leverages the same platform (IDS i10®) used for Volition's human cancer detection products.
- Japan's pet dog population of approximately seven million presents a significant revenue opportunity for Volition.
The big picture
Volition's automated vet cancer test marks a strategic shift towards high-throughput, centralized lab diagnostics in Japan, a market with high demand for early cancer detection in pets. The use of the same platform for human and veterinary tests underscores Volition's cross-industry synergy, potentially opening new revenue streams in both sectors. The partnership with Fujifilm Vet Systems, a leader in Japan's veterinary diagnostics, positions Volition to capitalize on a significant and growing market.
What we're watching
- Market Penetration
- How Volition will leverage Fujifilm's network to expand the Nu.Q® Vet Cancer Test beyond Japan.
- Revenue Growth
- Whether the automated test can meet the increasing demand and drive significant revenue from Japan's large pet market.
- Technological Synergy
- The pace at which Volition can integrate its human and veterinary diagnostic platforms for broader market applications.
Related topics